

The French National Cancer Institute (INCa) organized a high-level meeting within the frame of the European Partnership for Actions Against Cancer

This conference held on October 18 and 19, 2012 at the Cité Internationale Universitaire de Paris, addressed European coordination of research. Main public and private stakeholders of cancer research from 17 European countries attended the meeting that aimed at presenting new coordinated actions to impact European cancer research. Concrete, ambitious and innovating projects as well as new organisational models were discussed. INCa presented a potential CLIP² - like organisation to be developed at European level; this INCa project sponsors at national level, early-phase clinical trials for innovative drugs and is conducted with the pharma industry. Driven by the Italian partners, a second pilot project on the development of a platform dedicated to outcome research was discussed. A third potential pilot project on research prevention was presented by the Spanish partners. The European Partnership for Actions Against Cancer supports the EU member States for a better coordination of cancer activities and is structured around 4 main areas: health promotion and early detection, dissemination of good practices in cancer healthcare, cooperation and coordination in cancer research, and comparable information and data. INCa is an active member of the Partnership and co-leads the work package on "research coordination"

To see the Meeting Documents please click on the links below:

[The Programme of the Meeting](#)
[The Final Report of the Meeting](#)
[The Biographies of the speakers and panelists](#)

To see presentations presented at the Meeting please click on the links bellow:

18 OCTOBER 2012

Introduction / Purpose & expectations

[Agnès Buzyn, President, Institut National du Cancer, Co-leader EPAAC WP8](#)
[Julio E. Celis, ECCO Policy Committee, Danish Cancer Society, Leader EPAAC WP8](#)

Pilot Project 1: Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics

[Fabien Calvo, Deputy Director General, Institut National du Cancer: Overview on the implementation of the CLIP² program & the public-private partnership in early stages clinical trials in France: key steps and pre-requisites](#)

Panel discussion

Examples of similar public-private partnership in other European countries / Chairs: Jane Cope, NCRI (UK) and Fabien Calvo, INCa (FR)

[In the UK, Matthew Seymour, Director of the National Cancer Research Network](#)
[In Spain, Alejandro Piris, scientific manager, Vall d'Hebron Institute of Oncology](#)
[In Italy, Marco Pierotti, Scientific Director, Fondazione Istituto Nazionale dei Tumori, Milan](#)

Pilot Project 1: review of key steps & pre-requisites

Panel discussion

Designation of the early phase clinical centres / Chairs: Kate Miller, ECMC network, UK and Philippe Cassier, Coordinator CLIP² Léon Bérard, Lyon

Introduction

[Example in France, Philippe Cassier](#)
[In the UK, Kate Miller](#)
[Interface with biology infrastructures, Frédérique Nowak, Head of the innovation at INCa \(FR\)](#)
[A European approach – Possible way forwards and interactions, ECRIN \(European clinical research infrastructure network\), Jacques Demotes, programme coordinator at ECRIN](#)
[EATRIS \(European Advanced Translational Research Infrastructure\), Giovanni Migliaccio, EATRIS Scientific Director & Istituto Superiore di Sanità, Italy](#)
[OECI & BenchCan, Wim van Harten, President, Organisation of European Cancer Institutes](#)

Panel discussion

Funding models and organisation of the calls for proposals / Chairs: Nadine Houédé, Oncology Centre Bergonié (France) and Erica Hackenitz, ZonMW (The Netherlands)

[Introduction by N. Houédé and E. Hackenitz](#)
[Merel Hoozemans - Strik, Research coordinator, KWF Kankerbestrijding, NL](#)
[Béatrice Bussière, INCa](#)
[Michael Warmbold – VP Medical Affairs Oncology Europe, Pfizer](#)
[Jérôme Boichot, GE Healthcare](#)

19 OCTOBER 2012

Pilot Project 2: a European platform for outcomes research - Review of experiences & pre-requisites

[Overview of needs, challenges and opportunities, Maria Ferrantini, Ministry of Health, Italy - Istituto Superiore di Sanità](#)

Panel discussion

Key issues for optimizing data collection and use / Chair: Franco Berrino, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)

[EUROCARE High Resolution studies, Jean Faivre, Burgundy Digestive Cancer Registry, INSERM U866, University of Burgundy, University Hospital of Dijon \(France\)](#)

[Dutch studies linking registries' and clinical data, Jan Willem Coebergh, EURO COURSE Coordinator, International Benchmark Study](#)

Michel P. Coleman, Cancer Research UK Cancer Survival Group, (United Kingdom)

Pilot Project 2: a European platform for outcomes research – Need and feasibility

Panel discussion

Is the building of a cancer information system needed and feasible in Europe? Chair: Herman Brenner, German Cancer Research Center

[Cancer information and public health, Tit Albreht, National Institute of Public Health of Slovenia \(Slovenia\)](#)

[The EPAAC WP9 proposal of a European Cancer Information System \(ECIS\), Riccardo Capocaccia, Istituto Superiore di Sanità \(Italy\)](#)

Panel discussion

Cancer outcomes research: where to start from? Chairs: Ulrik Ringborg, EurocanPlatform Coordinator and Marco Pierotti, Scientific Director, Fondazione Istituto Nazionale dei Tumori, Milan (Italy)

[Outcomes research and clinical epidemiology in the EurocanPlatform project , Herman Brenner, German Cancer Research Center](#)

Clinical validation of biomarkers in archive tissues by multicentric studies Giorgio Stanta, chairman of the OEI Biobanks and Molecular Pathobiology Working Group

[Population data and clinical outcome research: opportunities and challenges, Milena Sant, EPAAC WP9 leader, Descriptive studies and health planning unit, Istituto nazionale tumori, Milano, Italy](#)

[Presentation of a potential Pilot Project 3: Prevention Carlos Segovia Perez, Instituto de Salud Carlos III, & Rosana Peiro, Centro Superior de Investigacion en Salud Publica, Spain](#)